Milan

• An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended recruitment
  2022-503040-41-00 4 2024-02-09 PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)
• Study of HRO761 alone or in combination in cancer patients with specific DNA alterations called Microsatellite Instability-High or Mismatch … Ended recruitment
  2022-502314-93-00 1 2024-02-05 MSIhi or dMMR advanced unresectable or metastatic solid tumors
• Study to evaluate the efficacy and safety of BGB-11417 in participants with Waldenström’s Macroglobulinemia Ended recruitment
  2023-503235-18-00 4 2024-01-31 previously untreated WM
• A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended recruitment
  2023-503288-40-00 5 2024-01-26 Unresectable or Metastatic Melanoma
• A Trial of Lu AG13909 in Participants with Congenital Adrenal Hyperplasia Ended recruitment
  2023-503711-15-00 7 2024-01-25 Congenital adrenal hyperplasia
• A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION717 in Patie … Ended recruitment
  2023-503355-98-00 7 2024-01-24 Prion diseases
• A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma … Ended recruitment
  2023-503575-21-00 5 2024-01-23 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
• Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended recruitment
  2023-503428-24-00 4 2024-01-19 Neoplasms, Head and Neck
• A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended recruitment
  2022-502442-27-00 5 2024-01-08 Obesity
• A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB … Ended recruitment
  2023-506139-13-00 5 2024-01-04 Treatment naïve patients with MF
• Tuvusertib (M1774) in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322) Ended recruitment
  2022-502010-85-00 9 2023-12-20 Non-Squamous Non-Small Cell Lung Cancer
• A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monothera … Ended recruitment
  2024-512573-27-01 4 2023-12-11 Muscle-invasive bladder cancer (MIBC)
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thy … Ended recruitment
  2023-503309-13-00 5 2023-11-29 Moderate-to-Severe Thyroid Eye Disease
• A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, TransCon TLR7/8 Agonist, or … Ended recruitment
  2023-509143-27-00 7 2023-11-27 Locally advanced or metastatic solid tumor malignancies, platinum resi
• Determine effectiveness of Anifrolumab In Systemic sclerosis Ended recruitment
  2023-505976-31-00 5 2023-11-24 Systemic Sclerosis (SSc) presenting with Limited or Diffuse Cutaneous
• Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended recruitment
  2023-503265-27-00 5 2023-11-23 Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
• Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended recruitment
  2023-505023-31-00 5 2023-11-17 Renal cell carcinoma
• A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M … Ended recruitment
  2022-501863-41-00 5 2023-11-13 Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
• Therapeutic vaccination: Phase I / II clinical study on patients randomized blinded to the experimental vaccine or placebo regimen. we want … Ended recruitment
  2024-514581-39-00 7 2023-11-08 HIV Infection
• A Phase 3b/4 Randomized, Double-Blind, Double-Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib V … Ended recruitment
  2022-502578-18-00 11 2023-11-07 Rheumatoid Arthritis
• A phase 1/2 study of SLN124 in patients with Polycythemia Vera Ended recruitment
  2023-503544-13-00 9 2023-11-02 Polycythemia Vera
• A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntingt … Ended recruitment
  2023-504628-24-00 4 2023-10-31 Huntington's Disease
• A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’ … Ended recruitment
  2022-502966-26-01 5 2023-10-27 Sjögren’s syndrome
• Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants with Multiple System Atrophy Ended recruitment
  2023-504876-12-00 5 2023-10-25 Neurogenic Orthostatic Hypotension

Showing 1,393–1,416 of 2,361 trials